Efficacy of remission-induction regimens for ANCA-associated vasculitis Academic Article uri icon

Overview

MeSH Major

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Antibodies, Monoclonal, Murine-Derived
  • Azathioprine
  • Cyclophosphamide
  • Immunologic Factors

abstract

  • In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months. (Funded by the National Institute of Allergy and Infectious Diseases and others; RAVE ClinicalTrials.gov number, NCT00104299.)

authors

publication date

  • August 5, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1213277

PubMed ID

  • 23902481

Additional Document Info

start page

  • 417

end page

  • 27

volume

  • 369

number

  • 5